President Trump announced Friday that his administration's direct-to-consumer drug platform, TrumpRx, is adding 160 new prescription medications, marking the second expansion in as many months. The move brings the total number of drugs available on TrumpRx.gov to more than 800, covering what the president says is four out of five prescriptions filled by Americans.
In a post on Truth Social, Trump touted the expansion as delivering "clear, transparent, and DISCOUNTED offerings" at highly reduced prices. The platform, which debuted in February with 43 branded drugs, now features two categories: "presidential deals" for brand-name medications and "standard prices" for generics. Drugs for asthma, infertility, and obesity are among those included.
The expansion is part of Trump's broader strategy to lower drug costs through his "most-favored-nation" (MFN) policy, which ties U.S. prices for certain brand-name drugs to the lowest prices paid by other developed nations. Health and Human Services Secretary Robert F. Kennedy Jr. has argued that Americans have been paying two to four times more than patients in other countries for the same medications.
Trump has frequently touted the MFN policy as a signature achievement, claiming in his State of the Union address that he accomplished what previous presidents "never could." On Friday, he asserted that the policy has saved Americans over $400 million since TrumpRx launched. He also linked the program's success to his use of tariffs, writing, "Most Favored Nations would not be possible without my use of TARIFFS, which are getting other Countries to 'pay up' instead of relying on American Patients getting ripped off."
The announcement comes weeks after billionaire investor Mark Cuban joined Trump at the White House to unveil the addition of 600 drugs to the platform. Cuban, whose own discount drug platform Cost Plus Drugs is collaborating with TrumpRx, said in April that the goal is to make medications inexpensive for everyone, regardless of party affiliation. "Republicans like cheap drugs, too. Independents like cheap drugs, too. Democrats like cheap drugs too," Cuban told Fox News, adding that the mission extends beyond drugs to all healthcare.
The expansion of TrumpRx has drawn attention amid broader political battles over healthcare costs and government spending. The program's reliance on tariffs and international price comparisons has sparked debate, with some GOP lawmakers pushing back on Trump's trade policies. Meanwhile, the administration continues to face scrutiny over its healthcare agenda as midterm elections approach.
Trump's focus on drug pricing has also been a key part of his appeal to working-class voters, though critics question the long-term sustainability of the MFN approach. The addition of 160 drugs is likely to keep the issue in the spotlight as the 2026 midterms near.
